» Articles » PMID: 30171206

Low Nadir CD4+ T-cell Counts Predict Gut Dysbiosis in HIV-1 Infection

Abstract

Human immunodeficiency virus (HIV)-1 infection causes severe gut and systemic immune damage, but its effects on the gut microbiome remain unclear. Previous shotgun metagenomic studies in HIV-negative subjects linked low-microbial gene counts (LGC) to gut dysbiosis in diseases featuring intestinal inflammation. Using a similar approach in 156 subjects with different HIV-1 phenotypes, we found a strong, independent, dose-effect association between nadir CD4+ T-cell counts and LGC. As in other diseases involving intestinal inflammation, the gut microbiomes of subjects with LGC were enriched in gram-negative Bacteroides, acetogenic bacteria and Proteobacteria, which are able to metabolize reactive oxygen and nitrogen species; and were depleted in oxygen-sensitive methanogenic archaea and sulfate-reducing bacteria. Interestingly, subjects with LGC also showed increased butyrate levels in direct fecal measurements, consistent with enrichment in Roseburia intestinalis despite reductions in other butyrate producers. The microbiomes of subjects with LGC were also enriched in bacterial virulence factors, as well as in genes associated with beta-lactam, lincosamide, tetracycline, and macrolide resistance. Thus, low nadir CD4+ T-cell counts, rather than HIV-1 serostatus per se, predict the presence of gut dysbiosis in HIV-1 infected subjects. Such dysbiosis does not display obvious HIV-specific features; instead, it shares many similarities with other diseases featuring gut inflammation.

Citing Articles

Exploring potential associations between the human microbiota and reservoir of latent HIV.

Marin-Sanchez N, Paredes R, Borgognone A Retrovirology. 2024; 21(1):21.

PMID: 39614246 PMC: 11605983. DOI: 10.1186/s12977-024-00655-w.


Alterations of the gut microbiome in HIV infection highlight human anelloviruses as potential predictors of immune recovery.

Boukadida C, Peralta-Prado A, Chavez-Torres M, Romero-Mora K, Rincon-Rubio A, Avila-Rios S Microbiome. 2024; 12(1):204.

PMID: 39420423 PMC: 11483978. DOI: 10.1186/s40168-024-01925-7.


Causal relationships between gut microbiota, plasma metabolites, and HIV infection: insights from Mendelian randomization and mediation analysis.

Hu J, Hu J, Han D Virol J. 2024; 21(1):204.

PMID: 39215321 PMC: 11365174. DOI: 10.1186/s12985-024-02480-1.


Translocating bacteria in SIV infection are not stochastic and preferentially express cytosine methyltransferases.

Flynn J, Ortiz A, Vujkovic-Cvijin I, Welles H, Simpson J, Castello Casta F Mucosal Immunol. 2024; 17(5):1089-1101.

PMID: 39089468 PMC: 11471372. DOI: 10.1016/j.mucimm.2024.07.008.


From dysbiosis to defense: harnessing the gut microbiome in HIV/SIV therapy.

Brenchley J, Serrano-Villar S Microbiome. 2024; 12(1):113.

PMID: 38907315 PMC: 11193286. DOI: 10.1186/s40168-024-01825-w.


References
1.
Antinori A, Coenen T, Costagiola D, Dedes N, Ellefson M, Gatell J . Late presentation of HIV infection: a consensus definition. HIV Med. 2010; 12(1):61-4. DOI: 10.1111/j.1468-1293.2010.00857.x. View

2.
Mocroft A, Lundgren J, Sabin M, Monforte A, Brockmeyer N, Casabona J . Risk factors and outcomes for late presentation for HIV-positive persons in Europe: results from the Collaboration of Observational HIV Epidemiological Research Europe Study (COHERE). PLoS Med. 2013; 10(9):e1001510. PMC: 3796947. DOI: 10.1371/journal.pmed.1001510. View

3.
Paiardini M, Muller-Trutwin M . HIV-associated chronic immune activation. Immunol Rev. 2013; 254(1):78-101. PMC: 3729961. DOI: 10.1111/imr.12079. View

4.
Deeks S . HIV infection, inflammation, immunosenescence, and aging. Annu Rev Med. 2010; 62:141-55. PMC: 3759035. DOI: 10.1146/annurev-med-042909-093756. View

5.
Battegay M, Fluckiger U, Hirschel B, Furrer H . Late presentation of HIV-infected individuals. Antivir Ther. 2007; 12(6):841-51. View